NTX 301
Alternative Names: NTX-301; XNTR-20-02Latest Information Update: 28 Feb 2024
At a glance
- Originator Southern Research
- Developer Pinotbio; Southern Research; Xennials Therapeutics
- Class Antineoplastics; Nucleosides
- Mechanism of Action DNA cytosine 5 methyltransferase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Glioma; Ovarian cancer; Solid tumours; Urogenital cancer
- No development reported Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Chronic-myelomonocytic-leukaemia(Second-line therapy or greater) in USA (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Second-line therapy or greater) in USA (PO)